F. Bert, 10-Fold increase (2006-11) in the rate of healthy subjects with extendedspectrum beta-lactamase-producing Escherichia coli faecal carriage in a Parisian checkup centre, J Antimicrob Chemother, vol.68, issue.3, pp.562-570, 2013.

J. Rodríguez-baño, L. López-cerero, M. Navarro, P. De-alba, and A. Pascual, Faecal carriage of extended-spectrum ??-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology, Journal of Antimicrobial Chemotherapy, vol.18, issue.1, pp.1142-1151, 2008.
DOI : 10.1017/S0950268806005917

L. Pallecchi, A. Bartoloni, C. Fiorelli, A. Mantella, D. Maggio et al., Rapid Dissemination and Diversity of CTX-M Extended-Spectrum ??-Lactamase Genes in Commensal Escherichia coli Isolates from Healthy Children from Low-Resource Settings in Latin America, Antimicrobial Agents and Chemotherapy, vol.51, issue.8, pp.2720-2725, 2007.
DOI : 10.1128/AAC.00026-07

A. Ibrahimagi?, B. Bedeni?, F. Kamberovi?, and S. Uzunovi?, High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings, Journal of Infection and Chemotherapy, vol.21, issue.5
DOI : 10.1016/j.jiac.2015.01.003

D. Burgess, R. Hall, and I. , In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae. Diagnostic microbiology and infectious disease, pp.41-47, 2004.

Y. Harada, Y. Morinaga, N. Kaku, S. Nakamura, N. Uno et al., In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.831-840, 2014.

K. Thomson and E. Moland, Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum beta -Lactamase-Producing Enterobacteriaceae, Antimicrobial Agents and Chemotherapy, vol.45, issue.12
DOI : 10.1128/AAC.45.12.3548-3554.2001

N. Wu, B. Chen, S. Tian, and Y. Chu, The inoculum effect of antibiotics against CTX-Mextended-spectrum ?-lactamase-producing Escherichia coli, Annals of Clinical Microbiology and Antimicrobials, vol.13, p.45, 2014.

J. Rodriguez-bano, E. Picon, M. Navarro, L. Lopez-cerero, and A. Pascual, Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.894-900, 2012.

C. Suankratay, K. Jutivorakool, and S. Jirajariyavej, A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamaseproducing bacteria, Journal of the Medical Association of Thailand = Chotmaihet thangphaet, vol.91, issue.8, pp.1172-81, 2008.

C. Bin, W. Hui, Z. Renyuan, N. Yongzhong, X. Xiuli et al., Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum betalactamase-producing Escherichia coli. Diagnostic microbiology and infectious disease, pp.351-358, 2006.

J. Rodriguez-bano, E. Picon, P. Gijon, J. Hernandez, M. Ruiz et al., Communityonset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.40-48, 2010.

P. Tamma, J. Han, C. Rock, A. Harris, E. Lautenbach et al., Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum beta-Lactamase Bacteremia. Clinical infectious diseases : an official publication of the, Infectious Diseases Society of America, vol.60, issue.9, pp.1319-1344, 2015.

P. Harris, M. Yin, R. Jureen, J. Chew, A. J. Paynter et al., Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrobial resistance and infection control beta-Lactam/betalactam inhibitor combinations for the treatment of bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.14167-74, 2012.

K. Vardakas, G. Tansarli, P. Rafailidis, and M. Falagas, Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ??-lactamases: a systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, vol.63, issue.2, pp.2793-803, 2012.
DOI : 10.1016/j.diagmicrobio.2008.11.004

M. Trivedi, V. Patel, R. Soman, C. Rodriguez, and T. Singhal, The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials, The Journal of the Association of Physicians of India, vol.60, pp.28-30, 2012.

R. Lepeule, E. Ruppe, P. Le, L. Massias, F. Chau et al., ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.56, issue.3
DOI : 10.1128/AAC.06233-11

C. Lee, L. Su, Y. Tang, and J. Liu, Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.1074-1081, 2006.
DOI : 10.1093/jac/dkl381

A. Doi, T. Shimada, S. Harada, K. Iwata, and T. Kamiya, The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, International Journal of Infectious Diseases, vol.17, issue.3, pp.159-63, 2013.
DOI : 10.1016/j.ijid.2012.09.010

C. Yang, S. Li, F. Chuang, C. Chen, C. Lee et al., Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis, BMC Infectious Diseases, vol.39, issue.Suppl 5, pp.206-247, 2012.
DOI : 10.1086/420816

C. Lee, C. Chu, J. Liu, Y. Chen, C. Chiu et al., Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 ??-lactamases, Journal of Antimicrobial Chemotherapy, vol.43, issue.2
DOI : 10.1086/503264

B. Pangon, C. Bizet, A. Bure, F. Pichon, A. Philippon et al., In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. The Journal of infectious diseases, pp.1005-1011, 1989.

M. Munoz-davila, Role of Old Antibiotics in the Era of Antibiotic Resistance

M. Rizvi, F. Khan, H. Sami, I. Shukla, and H. Khan, Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli Archives of internal medicine Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urology annals, pp.1897-90226, 2008.

J. Oteo, B. Orden, V. Bautista, O. Cuevas, M. Arroyo et al., CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin, Journal of Antimicrobial Chemotherapy, vol.61, issue.2, pp.712-719, 2009.
DOI : 10.1093/jac/dkm464

K. Yaita, M. Komatsu, Y. Oshiro, and Y. Yamaguchi, Postoperative Meningitis and Epidural Abscess due to Extended-spectrum ^|^beta;-Lactamase-producing Klebsiella pneumoniae: A Case Report and a Review of the Literature, Internal Medicine, vol.51, issue.18, pp.2645-2653, 2012.
DOI : 10.2169/internalmedicine.51.8068

R. Sinha and A. Bhakta, Extended spectrum beta lactamase peritonitis: Time for innovation? Indian journal of nephrology, pp.374-380, 2012.

S. Huang, M. Lee, H. Leu, S. Park, S. Choi et al., Bacteremia due to extended-spectrum beta-lactamaseproducing Enterobacteriaceae other than Escherichia coli and Klebsiella The efficacy of noncarbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli Clinical outcome of extendedspectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, pp.496-5022848, 2006.

S. Thibaut, J. Caillon, A. Marquet, G. Grandjean, G. Potel et al., Epidemiology of third-generation cephalosporin-resistant community-acquired Enterobacteria isolated from elderly patients, M??decine et Maladies Infectieuses, vol.44, issue.2, pp.57-62, 2014.
DOI : 10.1016/j.medmal.2013.11.008

M. Melzer and I. Petersen, Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli, Journal of Infection, vol.55, issue.3, pp.254-263, 2007.
DOI : 10.1016/j.jinf.2007.04.007

D. Paterson and R. Bonomo, Extended-Spectrum ??-Lactamases: a Clinical Update, Clinical Microbiology Reviews, vol.18, issue.4
DOI : 10.1128/CMR.18.4.657-686.2005

. Société-de-pathologie-infectieuse-en-langue-française, Diangnostic et antibiothérapie des infections urinaires bactériennes communautaires de l'adulte

C. Kang, S. Park, D. Chung, K. Peck, and J. Song, Piperacillin???tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum ??-lactamase-producing Escherichia coli and Klebsiella pneumoniae, Journal of Infection, vol.64, issue.5, pp.533-537, 2012.
DOI : 10.1016/j.jinf.2012.01.008

K. Lew, T. Ng, M. Tan, S. Tan, E. Lew et al., Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting, Journal of Antimicrobial Chemotherapy, vol.40, issue.5, pp.1219-1244, 2015.
DOI : 10.1097/CCM.0b013e3182416ecf

D. Rosa, F. Pagani, N. Fossati, L. Raviolo, S. Cometto et al., The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria, Infection, vol.11, issue.6, pp.555-61, 2011.
DOI : 10.1016/S1473-3099(11)70005-6

J. Rodriguez-bano, E. Picon, P. Gijon, J. Hernandez, J. Cisneros et al., Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-??-Lactamase-Producing Escherichia coli, Journal of Clinical Microbiology, vol.48, issue.5, pp.1726-1757, 2010.
DOI : 10.1128/JCM.02353-09

K. Laupland, D. Gregson, D. Church, T. Ross, and J. Pitout, Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.1041-1048, 2008.

E. Lautenbach, J. Patel, W. Bilker, P. Edelstein, and N. Fishman, Extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.1162-71, 2001.

J. , S. Sanchez, and J. , Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, pp.653-662, 2008.